Two recently filed lawsuits from Allergan PLC are teeing up a pivotal test of the extent to which drug compounders can mass-produce virtual copies of brand-name prescription drugs, attorneys say.
Continue reading the story on Law360.
'Seminal' Allergan Cases Test Copycat Drug Limits
